



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Alan Garen *et al.*

Serial No.: 10/030,203

Filed: December 31, 2001

For: NEOVASCULAR-TARGETED  
IMMUNOCONJUGATES

Group Art Unit: 1642

Examiner: TBA

Atty. Docket No. 006337.00004

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA. 22313

Sir:

Submitted herewith are one (1) sheet of Form PTO-1449 and a copy of the documents listed therein.


It is requested that the Examiner make his consideration of these documents formally of record with his initial action.

Since this Supplemental Information Disclosure Statement is being filed before issuance of a first Office Action on the merits under 37 C.F.R. 1.97(b), it is submitted that no fee or certification is required. However, if a fee is required, please charge our Deposit Account No. 19-0733.


Respectfully submitted,

Date: September 29, 2003

By:

  
Sarah A. Kagan  
Registration No. 32,141

Banner & Witcoff, Ltd.  
Customer No. 22907



Substitute for Form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

### Complete if Known

Application Number	10/030,203
Filing Date	December 31, 2001
First Named Inventor	Alan Garen
Group Art Unit	1642
Examiner Name	TBA
Attorney Docket Number	006337.00004

### U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		5,605,690	02/25/1997	Jacobs et al.	
		6,140,470	10/31/2000	Garen et al.	
		6,448,071	09/10/2002	Schneck et al.	

### FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		DAL PORTO et al., "A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations", <i>Proc. Natl. Acad. Sci. USA</i> , July 1993, pp. 6671-6675, Vol. 90.	
		EILAT et al., "Secretion of a soluble, chimeric $\gamma\delta$ T-cell receptor-immunoglobulin heterodimer", <i>Proc. Natl. Acad. Sci. USA</i> , August 1992, pp. 6871-6875, Vol. 89.	
		GRÉGOIRE et al., "Engineered secreted T-cell receptor $\alpha\beta$ heterodimers", <i>Proc. Natl. Acad. Sci. USA</i> , September 1991, pp. 8077-8081, Vol. 88.	
		MOHLER et al., "Soluble Tumor Necrosis Factor (TNF) Receptors Are Effective Therapeutic Agents in Lethal Endotoxemia and Function Simultaneously as Both TNF Carriers and TNF Antagonists", <i>J. Immunol.</i> , August 1993, pp. 1548-1561, Vol. 151, No. 3.	
		ERBEN et al., "Differential effects of a stem cell factor-immunoglobulin fusion protein on malignant and normal hematopoietic cells", <i>Cancer Res.</i> , June 1999, pp. 2924-30, Vol. 59, No. 12 (Abstract only).	
		BABA, E., "Effects of IgG-Fc-mitomycin C conjugate on cancer cells", <i>Hokkaido Igaku Zasshi</i> , March 1996, pp. 271-81, Vol. 71, No. 2 (Article in Japanese; abstract only).	
		PEPPEL et al., "A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity", <i>J. Exp. Med.</i> , December 1991, pp. 1483-9, Vol. 174, No. 6. (Abstract only).	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231